Stockwatch: Premature evaluation
This article was originally published in Scrip
The way the stock price of a life science company moves in response to an event can reveal a lot more than whether 'the market' thinks the event is good or bad news. Last week, for instance, stock movements implied that Human Genome Science might not be sold for as little as $13 per share, and that Vertex would have to work very hard to warrant the surge in its valuation that followed its announcement of positive data in cystic fibrosis.
You may also be interested in...
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.
Agios’s divestment of its oncology pipeline and commercial operations provided a rare case where all parties appeared satisfied. In many other cases, there are winners and losers.